A case review of a patient experience of photopheresis using a peripherally inserted central catheter

Extracorporeal photopheresis (ECP) is a cell based immunomodulatory therapy in which the patient is attached intravenously to a cell separating machine. During ECP a patient's blood is collected via either a central venous access device (CVAD) or a peripherally inserted 16G arterial venous fistula needle in either one or both antecubital fossa. However, patients presenting for ECP with GVHD repeatedly present a challenge to the ECP team due to poor venous access resulting from previous therapies and skin changes. The use of peripherally inserted central venous catheters (PICCs) offers an alternative route of vascular access for this cohort of patients. Here we present a case report of a patient successfully treated with ECP following the insertion of a PICC line.     

1,8-桉叶油素自微乳给药系统的制备及质量评价和细胞摄取研究

目的优化1,8-桉叶油素(1,8-cineole,1,8-Cin)自微乳给药系统(1,8-cineole self-microemulsion drug delivery system,1,8-Cin-SMEDDS)处方,对其进行表征并进行细胞摄取考察。方法通过绘制伪三元相图,确定1,8-Cin-SMEDDS有效自乳化区域,进行初步处方筛选。以粒径和载药量为指标,采用星点设计-效应面法对1,8-Cin-SMEDDS处方进行优化并验证。荧光显微镜观察高糖损伤的人脐静脉内皮细胞(HUVEC)对1,8-Cin-SMEDDS的摄取情况。结果 1,8-Cin-SMEDDS的最佳处方是大豆油(7.5%)与1,8-Cin(22.5%)为混合油相,HS15(56%)为乳化剂,乙醇(14%)为助乳化剂,滴加纯水至8m L得半透明略带蓝色乳光液体。透射电镜观察其外观呈球形液滴,激光粒度Zeta电位测定仪测得平均粒径为(131.68±1.44)nm,Zeta电位为(-10.03±1.63)m V;HPLC法测得包封率为(99.890±0.012)%,载药量为(224.750±0.028)mg/g。HUVEC细胞摄取实验结果表明,细胞对1,8-Cin-SMEDDS的摄取高于游离1,8-Cin。结论 1,8-Cin-SMEDDS制备方法简便,重复性好,所得1,8-Cin-SMEDDS外观良好,包封率高,理化性质稳定,且能促进细胞摄取。     

儿童中枢神经系统感染治疗疗程与腰椎穿刺检查系列建议之一——病毒性脑（膜）炎治疗疗程与腰椎穿刺检查建议

中枢神经系统感染是儿童神经系统常见疾病,也是临床住院的常见病种;中枢神经系统感染的病原以细菌和病毒感染较为常见,而结核菌、真菌、支原体感染相对少见;不同病原的中枢神经系统感染临床上有其共性表现又有不同病原感染疾病的特点;中枢神经系统感染的诊断包括病原学确诊或临床疑诊;不同的治疗转归其治疗疗程或腰穿检查与复查时间均缺乏研究性证据,困扰临床一线工作。为此,中华医学会儿科学分会神经学组组织的专家组制订了“儿童中枢神经系统感染治疗疗程与腰椎穿刺检查系列建议”,希望能为这一疾病的诊治提供参考。     

非那雄胺在慢性中心性浆液性脉络膜视网膜病变患者中的应用

目的评估非那雄胺治疗慢性中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy,CSC)的有效性及安全性。方法选取2017年3月至2019年6月在本院确诊的慢性CSC患者31例40眼,采用单臂试验对患者进行非那雄胺治疗。使用非那雄胺治疗后6个月,对患者的视网膜神经上皮层(retinal neuroepithelial layer,RNL)下积液状况,ETDRS视力以及黄斑中心凹视网膜厚度(central foveal thickness,CFT)进行检查。结果非那雄胺治疗后1个月,有10眼(25.0%)RNL下积液完全消退。持续治疗2个月、3个月、4个月、5个月、6个月,分别有7眼(17.5%)、6眼(15.0%)、7眼(17.5%)、3眼(7.5%)及3眼(7.5%)RNL下积液消退,仅有4眼(10.0%)在治疗后6个月RNL下积液仍存在。患眼EDTRS视力非那雄胺治疗后1个月为(50.00±16.11)个字母,与治疗前(46.16±16.67)个字母差异无统计学意义(P=0.2213);治疗后2个月(53.39±14.67)个字母,较治疗前显著升高(P=0.0003);治疗后3个月、4个月、5个月、6个月,分别为(57.39±12.76)个字母、(58.52±12.39)个字母、(59.13±10.76)个字母及(60.42±10.96)个字母,与治疗前相比差异均有统计学意义(均为P<0.0001)。而患眼CFT自治疗后1个月、2个月、3个月、4个月、5个月、6个月分别为(274.10±22.74)μm、(273.00±17.22)μm、(263.50±12.81)μm、(263.90±10.62)μm、(259.70±12.48)μm及(252.60±11.00)μm,与治疗前(296.60±35.41)μm相比,差异均有统计学意义(均为P<0.05)。所有患者均无服药后身体不适或并发症发生。结论非那雄胺对于慢性CSC的治疗安全且有效,有望成为慢性CSC的治疗选择。     

肥胖相关性高血压患者中心动脉压与靶器官损害相关性分析

【摘要】目的 探讨肥胖相关性高血压患者靶器管损害程度及中心动脉压（CBP）对靶器管损害的影响。方法 纳入徐州市中心医院2014年6月至2019年6月收住入院的高血压患者150例。根据高血压患者体质量指数，将样本分为正常体重高血压组（BMI<24Kg/m2）、超重高血压组(24 Kg/m2≤BMI<28 Kg/m2)、肥胖高血压组（BMI≥28 Kg/m2）。比较三组患者靶器管损害的差异及其与中心动脉压、24小时动态血压的相关性。结果 (1)与正常体重高血压组、超重高血压组比较，肥胖高血压组BMI、腰围、空腹血糖、同型半胱氨酸（HCY）、高密度脂蛋白（HDL-C）、低密度脂蛋白（LDL-c）、颈-股脉搏波传导速度(c-fPWV)、左心室质量（LVM）、左心室质量指数（LVMI）、尿微量白蛋白（mALB）较高（P<0.05）。(2)高血压患者c-fPWV与中心动脉脉压差（CPP）呈正相关（r=0.580，P=0.001）；LVMI与中心动脉收缩压（CSBP）呈正相关（r=0.279，P=0.004）；mALB与CSBP呈正相关（r=0.333，P=0.001）。结论 体重增加可进一步加重高血压患者靶器管损害，中心动脉压较24小时动态血压对高血压患者靶器管损害更为密切。     

大鼠急性经口1,1-二氨基-2,2-二硝基乙烯的毒代动力学研究

建立大鼠血液中1,1-二氨基-2,2-二硝基乙烯(FOX-7)的检测方法，将30只健康SPF级SD大鼠随机分为空白对照组、200和500mg/kgFOX-7染毒组，每组10只。采用一次性经口灌胃方式染毒，染毒容量为ImL/lOOg。于染毒后第0.5、1、2、4、8、12、24h对大鼠进行眼眶后静脉丛采血，使用紫外可见分光光度计检测血中FOX-7浓度。使用PhoenixWinNonlin6.1软件进行血药浓度-时间数据分析与毒代参数计算。大鼠单次灌胃FOX-7200和500mg/kg后，药-时曲线下面积AUC(0-24)分别为(27.01±L94)^g/(h?L)和(29.26±3.31)^^(h-L),AUC(0-?>分别为(42.。1±2.18)阿/(h-L)和(4L51±3.66)Mg/(h?L)；达峰浓度Cmax分别为(1.82±0,12)Mg/ml和(2.33±0,20)阿/ml,达峰时间y.为2h；半衰期知2分别为(10.83±2,77)h和(8.66±3,01)h。本研究为FOX-7毒代动力学模型的完善提供了科学依据。     

Perplexing condition of child full immunisation in economically better off Gujarat in India: An assessment of associated factors

BackgroundDespite decent progress in Children Full Immunisation (CFI) in India during the last decade, surprisingly, Gujarat, an economically more developed state, had the second-lowest coverage of CFI (50%) in the country, lower than economically less developed states such as Bihar (62%). Further, the proportion of children with no immunisation in Gujarat has risen from 5% in 2005 to 9% in 2016. This paper investigated factors associated with the low level of CFI coverage in Gujarat.MethodsThe study used two types of datasets: (1) the information on immunisation from 7730 children aged 12–23 months and their mothers from the fourth round of the Gujarat chapter of National Family Health Survey (NFHS 2015–16). (2) A macro (district) level data on both supply and demand-side factors of CFI are compiled from multiple sources. Bivariate and multivariate linear and logistic regression techniques were employed to identify the factors associated with CFI coverage.ResultsIn Gujarat, during 2015–2016, 50% of children aged 12–23 months did not receive full immunisation. The odds of receiving CFI was higher among children whose mothers had a Maternal and Child Protection (MCP) card (OR: 1.97, 95% CI 1.48–2.60) and those who received “high” maternal health services utilisation (OR: 1.59, 95% CI 1.10–2.26) compared to their counterparts. The odds of receiving CFI was about three times higher among the richest households (OR: 6.50, 95% CI 3.75–11.55) compared to their counterparts in the poorer households. Macro-level analyses suggest that poverty, maternal health care, and higher-order births are defining factors of CFI coverage in Gujarat.ConclusionsIn order of importance, focusing on poverty, economic inequalities, pregnancy registration, and maternal health care services utilisation are likely to improve receiving CFI uptake in Gujarat. The disadvantageous position of urban areas and non-scheduled tribes in CFI coverage needs further investigation.